JP2013542261A - ピペリジノンカルボキサミドインダンｃｇｒｐ受容体アンタゴニスト - Google Patents

ピペリジノンカルボキサミドインダンｃｇｒｐ受容体アンタゴニスト Download PDF

Info

Publication number
JP2013542261A
JP2013542261A JP2013538872A JP2013538872A JP2013542261A JP 2013542261 A JP2013542261 A JP 2013542261A JP 2013538872 A JP2013538872 A JP 2013538872A JP 2013538872 A JP2013538872 A JP 2013538872A JP 2013542261 A JP2013542261 A JP 2013542261A
Authority
JP
Japan
Prior art keywords
hydrogen
methyl
pharmaceutically acceptable
acid
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013538872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542261A5 (enExample
Inventor
ベル，イアン・エム
フレイリー，マーク・イー
ガリツチオ，ステイーブン・エヌ
ジネツテイ，アンソニー
ミツチエル，ヘレン・ジエイ
パオーネ，ダニエル・ブイ
スターズ，ドネツテ・デイー
ワン，チエン
ザートマン，ブレア・シー
ステイーブンソン，ヘザー・イー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of JP2013542261A publication Critical patent/JP2013542261A/ja
Publication of JP2013542261A5 publication Critical patent/JP2013542261A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2013538872A 2010-11-12 2011-11-10 ピペリジノンカルボキサミドインダンｃｇｒｐ受容体アンタゴニスト Ceased JP2013542261A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41308210P 2010-11-12 2010-11-12
US61/413,082 2010-11-12
US201061425039P 2010-12-20 2010-12-20
US61/425,039 2010-12-20
PCT/US2011/060083 WO2012064911A1 (en) 2010-11-12 2011-11-10 Piperidinone carboxamide indane cgrp receptor antagonists

Publications (2)

Publication Number Publication Date
JP2013542261A true JP2013542261A (ja) 2013-11-21
JP2013542261A5 JP2013542261A5 (enExample) 2014-12-25

Family

ID=46051295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538872A Ceased JP2013542261A (ja) 2010-11-12 2011-11-10 ピペリジノンカルボキサミドインダンｃｇｒｐ受容体アンタゴニスト

Country Status (6)

Country Link
US (2) US8883807B2 (enExample)
EP (1) EP2637656B1 (enExample)
JP (1) JP2013542261A (enExample)
AU (1) AU2011326455A1 (enExample)
CA (1) CA2816974A1 (enExample)
WO (1) WO2012064911A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516946A (ja) * 2012-03-14 2015-06-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｇｒｐ受容体アンタゴニストの製造方法
WO2019093284A1 (ja) * 2017-11-07 2019-05-16 キッセイ薬品工業株式会社 縮合複素環化合物
JP2022535994A (ja) * 2019-06-12 2022-08-10 ヘプタレス セラピューティクス リミテッド Ｃｇｒｐアンタゴニスト化合物
JP2025514364A (ja) * 2022-04-29 2025-05-02 熙源安健医▲薬▼（北京）有限公司 ピペリジンカルボキサミドアザインダン誘導体、その調製方法及び使用
US12344621B2 (en) 2019-06-12 2025-07-01 Nxera Pharma Uk Limited CGRP antagonist compounds

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064911A1 (en) * 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane cgrp receptor antagonists
TWI501968B (zh) * 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
CA2830348A1 (en) * 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
WO2012129013A1 (en) 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
WO2024134683A1 (en) * 2022-12-21 2024-06-27 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of intermediate compounds used in the treatment of migraine
CN119431222B (zh) * 2024-11-04 2025-10-17 杭州澳赛诺生物科技有限公司 一种不对称合成乌布吉泮手性中间体的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008512480A (ja) * 2004-09-13 2008-04-24 メルク エンド カムパニー インコーポレーテッド カルボキサミドスピロラクタムｃｇｒｐ受容体拮抗薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288559B2 (en) * 2003-03-14 2007-10-30 Merck + Co, Inc. Carboxamide spirohydantoin CGRP receptor antagonists
JP2008512460A (ja) * 2004-09-08 2008-04-24 メルク エンド カムパニー インコーポレーテッド 単環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬
EP1861399B1 (en) * 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
US7951795B2 (en) * 2006-12-08 2011-05-31 Merck Sharp & Dohme Corp. Constrained spirocyclic compounds as CGRP receptor antagonists
CA2689217C (en) * 2007-06-05 2016-02-16 Merck & Co., Inc. Carboxamide heterocyclic cgrp receptor antagonists
WO2012064911A1 (en) * 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane cgrp receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008512480A (ja) * 2004-09-13 2008-04-24 メルク エンド カムパニー インコーポレーテッド カルボキサミドスピロラクタムｃｇｒｐ受容体拮抗薬

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516946A (ja) * 2012-03-14 2015-06-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｇｒｐ受容体アンタゴニストの製造方法
JP2018030858A (ja) * 2012-03-14 2018-03-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｇｒｐ受容体アンタゴニストの製造方法
WO2019093284A1 (ja) * 2017-11-07 2019-05-16 キッセイ薬品工業株式会社 縮合複素環化合物
JP2022535994A (ja) * 2019-06-12 2022-08-10 ヘプタレス セラピューティクス リミテッド Ｃｇｒｐアンタゴニスト化合物
JP7556893B2 (ja) 2019-06-12 2024-09-26 ネクセラ・ファーマ・ユーケイ・リミテッド Ｃｇｒｐアンタゴニスト化合物
US12344621B2 (en) 2019-06-12 2025-07-01 Nxera Pharma Uk Limited CGRP antagonist compounds
JP2025514364A (ja) * 2022-04-29 2025-05-02 熙源安健医▲薬▼（北京）有限公司 ピペリジンカルボキサミドアザインダン誘導体、その調製方法及び使用

Also Published As

Publication number Publication date
US20130231358A1 (en) 2013-09-05
EP2637656A1 (en) 2013-09-18
US8883807B2 (en) 2014-11-11
US9499541B2 (en) 2016-11-22
EP2637656A4 (en) 2014-04-23
US20150031716A1 (en) 2015-01-29
CA2816974A1 (en) 2012-05-18
WO2012064911A1 (en) 2012-05-18
EP2637656B1 (en) 2016-12-14
AU2011326455A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
JP5642883B2 (ja) ピペリジノンカルボキサミドアザインダンｃｇｒｐ受容体アンタゴニスト
US8883807B2 (en) Piperidinone carboxamide indane CGRP receptor antagonists
EP2846798B1 (en) Aliphatic spirolactam cgrp receptor antagonists
US9409916B2 (en) Piperidinone carboxamide spirohydantoin CGRP receptor antagonists
JP2014508170A (ja) ピペリジノンカルボキサミドスピロヒダントインｃｇｒｐ受容体アンタゴニスト
JP2012511500A (ja) Ｃｇｒｐ受容体アンタゴニストとしての分岐末端を有する非アミドリンカー
HK1200163B (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
HK1183862A1 (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
HK1183862B (en) Piperidinone carboxamide azaindane cgrp receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151002

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151110

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20160322